Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX · · 9 pages · English
Summary by 6ix AI
The report highlights advancements in the Sofra technology platform, which aims to enhance cancer treatment efficacy and has garnered attention from international conferences and publications. Financially, the company reported cash reserves and net cash outflows from operating activities, while exploring options for securing additional capital. Noxopharm's ongoing research and collaborations are aimed at addressing autoimmune diseases and improving mRNA therapies, reflecting its commitment to innovation in the biotech sector.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Noxopharm
- SOF-SKN manufacturing begins to ensure clinical trial readi
- New data confirms cancer-fighting potential
- Noxopharms Sofra assets to be presented at global conference
- Noxopharm progresses US regulatory strategy
- New data shows SOF-SKN active ingredient efficacy
Later from Noxopharm
- New preclinical data supports immuno-oncology approach
- Appendix 4E - Preliminary Financial Report
- Novel oligonucleotides data presented at Options Conference
- Trading Halt
- Voluntary Suspension
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm